FR3119987B1 - Composition hydrogel et ses utilisations dans la prévention et/ou le traitement des dommages cutanés causés par les rayonnements - Google Patents

Composition hydrogel et ses utilisations dans la prévention et/ou le traitement des dommages cutanés causés par les rayonnements Download PDF

Info

Publication number
FR3119987B1
FR3119987B1 FR2101620A FR2101620A FR3119987B1 FR 3119987 B1 FR3119987 B1 FR 3119987B1 FR 2101620 A FR2101620 A FR 2101620A FR 2101620 A FR2101620 A FR 2101620A FR 3119987 B1 FR3119987 B1 FR 3119987B1
Authority
FR
France
Prior art keywords
treatment
prevention
skin
hydrogel composition
radiation damage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2101620A
Other languages
English (en)
Other versions
FR3119987A1 (fr
Inventor
Gareth Winckle
Philippe Andres
Janusz Czernielewski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tarian Pharma SAS
Original Assignee
Tarian Pharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR2101620A priority Critical patent/FR3119987B1/fr
Application filed by Tarian Pharma SAS filed Critical Tarian Pharma SAS
Priority to JP2023550646A priority patent/JP2024507266A/ja
Priority to US18/264,286 priority patent/US20240100044A1/en
Priority to CA3204652A priority patent/CA3204652A1/fr
Priority to CN202280015187.5A priority patent/CN116887813A/zh
Priority to EP22706811.1A priority patent/EP4294370A1/fr
Priority to AU2022224394A priority patent/AU2022224394A1/en
Priority to KR1020237031798A priority patent/KR20230147668A/ko
Priority to PCT/EP2022/054037 priority patent/WO2022175428A1/fr
Publication of FR3119987A1 publication Critical patent/FR3119987A1/fr
Application granted granted Critical
Publication of FR3119987B1 publication Critical patent/FR3119987B1/fr
Priority to ZA2023/06750A priority patent/ZA202306750B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L’invention concerne une composition sous une forme adaptée à une administration par voie topique à base d’eau comprenant un vasoconstricteur. L’invention se caractérise en ce que la composition comprend un vasoconstricteur choisi parmi la brimonidine ou ses sels, dans une phase solvantée comprenant : - du polyéthylène glycol en combinaison avec du propylène glycol et/ou du diméthylsulfoxyde (DMSO) ; - un copolymère Polyvinylpyrrolidone/Vinyl Acetate comme agent filmogène hydrophile ; - de la glycérine ; et en ce qu’elle se présente sous forme d’hydrogel. L’invention concerne également la composition selon l’invention pour son utilisation en tant que médicament, plus particulièrement dans la prévention et/ou le traitement de dermatite résultant d’un rayonnement notamment dans le cadre d’un traitement par radiothérapie. Figure 9
FR2101620A 2021-02-19 2021-02-19 Composition hydrogel et ses utilisations dans la prévention et/ou le traitement des dommages cutanés causés par les rayonnements Active FR3119987B1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR2101620A FR3119987B1 (fr) 2021-02-19 2021-02-19 Composition hydrogel et ses utilisations dans la prévention et/ou le traitement des dommages cutanés causés par les rayonnements
PCT/EP2022/054037 WO2022175428A1 (fr) 2021-02-19 2022-02-18 Composition hydrogel et ses utilisations dans la prévention et/ou le traitement des dommages cutanés causés par les rayonnements
CA3204652A CA3204652A1 (fr) 2021-02-19 2022-02-18 Composition hydrogel et ses utilisations dans la prevention et/ou le traitement des dommages cutanes causes par les rayonnements
CN202280015187.5A CN116887813A (zh) 2021-02-19 2022-02-18 水凝胶组合物及其在预防和/或治疗由辐射引起的皮肤损伤中的用途
EP22706811.1A EP4294370A1 (fr) 2021-02-19 2022-02-18 Composition hydrogel et ses utilisations dans la prévention et/ou le traitement des dommages cutanés causés par les rayonnements
AU2022224394A AU2022224394A1 (en) 2021-02-19 2022-02-18 Hydrogel composition and uses thereof in the prevention and/or treatment of skin damage caused by radiation
JP2023550646A JP2024507266A (ja) 2021-02-19 2022-02-18 ヒドロゲル組成物、ならびに放射線によって引き起こされる皮膚損傷の予防および／または処置におけるその使用
US18/264,286 US20240100044A1 (en) 2021-02-19 2022-02-18 Hydrogel composition and uses thereof in the prevention and/or treatment of skin damage caused by radiation
KR1020237031798A KR20230147668A (ko) 2021-02-19 2022-02-18 방사선으로 인한 피부 손상의 예방 및/또는 치료에 있어서의 하이드로겔 조성물 및 이의 용도
ZA2023/06750A ZA202306750B (en) 2021-02-19 2023-06-30 Hydrogel composition and uses thereof in the prevention and/or treatment of skin damage caused by radiation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2101620 2021-02-19
FR2101620A FR3119987B1 (fr) 2021-02-19 2021-02-19 Composition hydrogel et ses utilisations dans la prévention et/ou le traitement des dommages cutanés causés par les rayonnements

Publications (2)

Publication Number Publication Date
FR3119987A1 FR3119987A1 (fr) 2022-08-26
FR3119987B1 true FR3119987B1 (fr) 2023-01-13

Family

ID=75278238

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2101620A Active FR3119987B1 (fr) 2021-02-19 2021-02-19 Composition hydrogel et ses utilisations dans la prévention et/ou le traitement des dommages cutanés causés par les rayonnements

Country Status (10)

Country Link
US (1) US20240100044A1 (fr)
EP (1) EP4294370A1 (fr)
JP (1) JP2024507266A (fr)
KR (1) KR20230147668A (fr)
CN (1) CN116887813A (fr)
AU (1) AU2022224394A1 (fr)
CA (1) CA3204652A1 (fr)
FR (1) FR3119987B1 (fr)
WO (1) WO2022175428A1 (fr)
ZA (1) ZA202306750B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4306112A1 (fr) * 2022-07-15 2024-01-17 Tarian Pharma Nouveau regime posologique d'une composition comprenant de la brimonidine pour son utilisation dans la prevention et le traitement des dommages cutanes resultant d'un rayonnement

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150119401A1 (en) * 2008-08-01 2015-04-30 Eye Therapies, Llc Compositions and Methods for the Treatment of Nasal Conditions
WO2018218116A1 (fr) * 2017-05-26 2018-11-29 Scott Whitcup Composition topique de traitement de la rosacée et procédé de traitement de la rosacée avec celle-ci

Also Published As

Publication number Publication date
CN116887813A (zh) 2023-10-13
EP4294370A1 (fr) 2023-12-27
WO2022175428A1 (fr) 2022-08-25
CA3204652A1 (fr) 2022-08-25
US20240100044A1 (en) 2024-03-28
JP2024507266A (ja) 2024-02-16
AU2022224394A1 (en) 2023-09-21
KR20230147668A (ko) 2023-10-23
ZA202306750B (en) 2024-02-28
FR3119987A1 (fr) 2022-08-26

Similar Documents

Publication Publication Date Title
US10881672B2 (en) Pharmaceutical tetracycline composition for dermatological use
US20220008555A1 (en) Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery
NZ571819A (en) External pharmaceutical composition comprising luliconazole and either N-methyl-2-pyrrolidone, propylene carbonate or crotamiton
AU2013323766B2 (en) Topical ketoprofen composition
EP2364692A3 (fr) Compositions comprenant au moins un derive de l'acide naphtoïque, du peroxyde de benzoyle et au moins un agent filmogene, leurs procedes de preparation, et leurs utilisations
EA200601724A1 (ru) Новые композиции для местной доставки
FR2961694A1 (fr) Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
CN111904926B (zh) 局部用双氯芬酸钠组合物
US8636988B2 (en) Composition for treatment of sunburned skin
MA20150062A1 (fr) Composition topique semi-solide contenant de la pirfénidone et de l'oxyde de disulfure dialyle modifié (odd-m) pour éliminer ou prévenir l'acné
FR3119987B1 (fr) Composition hydrogel et ses utilisations dans la prévention et/ou le traitement des dommages cutanés causés par les rayonnements
FR3119986B1 (fr) Composition émulsion eau dans huile et ses utilisations dans la prévention et/ou le traitement des dommages cutanés causés par les rayonnements
EP0996442B1 (fr) Composition pharmaceutique liquide aqueuse contenant un derive de benzopyranne en tant que principal constituant
AR069831A1 (es) Composiciones y metodos para el tratamiento del cancer de vejiga
FR2802097A1 (fr) Composition sous forme de gel prevue pour recevoir un principe actif en solution ou en suspension, notamment pour application sur une muqueuse et procede de fabrication
Yamamoto et al. Deep dermatophytosis during topical tacrolimus therapy for psoriasis.
JP2018520110A (ja) リポ酸および粘膜模倣ポリマーを含んでなる眼科用組成物
JPH0231052B2 (fr)
WO2007138233A2 (fr) Utilisation du zatosetron pour le traitement de la rosacee
EP3329910B1 (fr) Composition pharmaceutique permettant de prévenir ou de traiter l'onychomycose et procédé de préparation associé
US20240016762A1 (en) Dual analgesic/anti-inflammatory compositions comprising cb2 receptor agonists, combinations, and methods of use thereof
JP2008150344A (ja) 半固形状鎮痒用外用製剤
EP1874291B1 (fr) Utilisation du gluconate de zinc pour le traitement de l'hidradenite suppuree
MA49557B1 (fr) Formulations à action prolongée
WO2021102072A1 (fr) Composition et procédé de traitement de la peau

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20220826

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4